LEADER 02360nam 22004813 450 001 9910964172203321 005 20251121193706.0 010 $a1-58528-581-1 035 $a(CKB)4100000004827102 035 $a(MiAaPQ)EBC5412768 035 $a(Au-PeEL)EBL5412768 035 $a(OCoLC)1039079127 035 $a(EXLCZ)994100000004827102 100 $a20251121d2018 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBiosimilars and Biologics $eImplementation and Monitoring in a Health Care Setting 205 $a1st ed. 210 1$aBethesda :$cAmerican Society of Health-System Pharmacists,$d2018. 210 4$dİ2018. 215 $a1 online resource (192 pages) 311 08$a1-58528-580-3 327 $aA new type of blockbuster : the growth of biologics -- De?ja? vu or something new? : comparing the generics and biosimilars experiences -- Bugs and drugs, and yeast and mice, and Chinese hamsters -- The $250 billion pyramid : analytics in biosimilarity determination -- The global biosimilars experience -- The American biosimilar experience : red, white, and possibly interchangeable -- Biosimilar clinical trial requirements -- Immunogenicity and pharmacovigilance in the biosimilar era -- The patent dance and the exclusivity shuffle -- Defining biosimilar value and other impossible tasks -- Biosimilar formulary management strategies. 330 $aAmong the most anticipated and discussed segments of the pharmaceutical market, biosimilars are finally beginning to exert a greater impact on practice. ASHP's Biosimilars & Biologics: Implementation and Monitoring in a Healthcare Setting is an authoritative, evidence-based resource that provides an in-depth perspective on all areas related to these innovative drugs. 517 $aBiosimilars and Biologics 606 $aBiosimilar Pharmaceuticals 606 $aDrug Compounding 606 $aDrug Monitoring 615 12$aBiosimilar Pharmaceuticals. 615 22$aDrug Compounding. 615 22$aDrug Monitoring. 676 $a615.1/9 700 $aLucio$b Steven$01857926 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910964172203321 996 $aBiosimilars and Biologics$94459071 997 $aUNINA